Factors influencing the durability of the glucose‐lowering effect of sitagliptin combined with a sulfonylurea. Issue 4 (11th February 2014)

• Record Type: Journal Article
• Authors: Kubota, Akira; Yabe, Daisuke; Kanamori, Akira; Kuroe, Akira; Takahashi, Nobuo; Saito, Tatsuhiko; Matsuba, Ikuro; Nabe, Koichiro; Kurose, Takeshi; Seino, Yutaka
• Is Part Of: Journal of diabetes investigation. Volume 5:Issue 4(2014:Aug.)
• Page Start: 445
• Page End: 448
• Publication Date: 2014-02-11
• Subjects: Diabetes -- Periodicals; Diabetes -- Research -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462005
• DOI: 10.1111/jdi.12182
• Languages: English
• ISSNs: 2040-1116

Abstract

<abstract abstract-type="main" id="jdi12182-abs-0001"> <title>Abstract</title> <p>We analyzed the changes of glycemic control over 12 months and the factors influencing blood glucose in 162 Japanese patients with type 2 diabetes having inadequate glycemic control despite sulfonylurea‐based therapy who received add‐on sitagliptin. Hemoglobin A1c (HbA1c) decreased significantly after 4 weeks of treatment, and this improvement was maintained for 1 year, although HbA1c was slightly higher in week 52 than in week 24. Comparison of the patients showing a ≥0.4% increase of HbA1c between weeks 24 and 52 (<italic>n</italic> = 57) with the others (<italic>n</italic> = 105) showed a significant difference in the change of bodyweight, as well as the dose of glibenclamide (both <italic>P </italic>&lt; 0.01). Although combined therapy with sitagliptin and a sulfonylurea seems to be effective for at least 1 year, blood glucose levels are more likely to increase again in patients who show greater weight gain after 24 weeks of treatment and those receiving a higher dose of glibenclamide.</p> </abstract>